Daniela Alberati
Basel, BS 4070, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Glycine Transporter Type I (GlyT1) Inhibitor, Bitopertin: A Journey from Lab to Patient.
Journal: Chimia
Published: August 31, 2018
Assessment of a glycine uptake inhibitor in animal models of effort-related choice behavior: implications for motivational dysfunctions.
Journal: Psychopharmacology
Published: October 04, 2016
Effects of GlyT1 inhibition on erythropoiesis and iron homeostasis in rats.
Journal: Experimental hematology
Published: May 03, 2016
Preclinical Reproductive and Developmental Toxicity Profile of a Glycine Transporter Type 1 (Glyt1) Inhibitor.
Journal: Birth defects research. Part B, Developmental and reproductive toxicology
Published: April 14, 2016
Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers.
Journal: Psychopharmacology
Published: September 22, 2015
Alterations in High-Frequency Neuronal Oscillations in a Cynomolgus Macaque Test of Sustained Attention Following NMDA Receptor Antagonism.
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Published: May 18, 2015
Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
Journal: JAMA psychiatry
Published: April 04, 2014
3-Amido-3-aryl-piperidines: A Novel Class of Potent, Selective, and Orally Active GlyT1 Inhibitors.
Journal: ACS medicinal chemistry letters
Published: January 06, 2014
Physiologically based pharmacokinetic modelling to predict single- and multiple-dose human pharmacokinetics of bitopertin.
Journal: Clinical pharmacokinetics
Published: April 18, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026